| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2.
|
Science
|
2002
|
4.45
|
|
2
|
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
|
Blood
|
2008
|
3.52
|
|
3
|
Mammalian defensins in immunity: more than just microbicidal.
|
Trends Immunol
|
2002
|
3.52
|
|
4
|
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
|
J Clin Oncol
|
2011
|
3.40
|
|
5
|
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
|
Br J Haematol
|
2013
|
2.01
|
|
6
|
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.
|
Nat Med
|
2005
|
1.63
|
|
7
|
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma.
|
Blood
|
2009
|
1.61
|
|
8
|
Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies.
|
Cancer Cell
|
2006
|
1.58
|
|
9
|
TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
|
Blood
|
2012
|
1.47
|
|
10
|
Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis.
|
Cancer Cell
|
2007
|
1.45
|
|
11
|
Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
|
Br J Haematol
|
2014
|
1.43
|
|
12
|
Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells.
|
Blood
|
2006
|
1.30
|
|
13
|
DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses.
|
Blood
|
2002
|
1.30
|
|
14
|
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma.
|
Clin Cancer Res
|
2008
|
1.29
|
|
15
|
Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.
|
Blood
|
2007
|
1.26
|
|
16
|
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.
|
Blood
|
2006
|
1.22
|
|
17
|
Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.
|
Blood
|
2005
|
1.21
|
|
18
|
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
|
Blood
|
2012
|
1.19
|
|
19
|
An NKT-mediated autologous vaccine generates CD4 T-cell dependent potent antilymphoma immunity.
|
Blood
|
2007
|
1.18
|
|
20
|
Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray.
|
Lab Invest
|
2004
|
1.18
|
|
21
|
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
|
J Clin Oncol
|
2012
|
1.17
|
|
22
|
Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts.
|
Blood
|
2007
|
1.12
|
|
23
|
Autologous lymphoma vaccines induce human T cell responses against multiple, unique epitopes.
|
J Clin Invest
|
2004
|
1.10
|
|
24
|
Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone.
|
J Mol Med (Berl)
|
2011
|
1.10
|
|
25
|
An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
|
J Control Release
|
2011
|
1.07
|
|
26
|
Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
|
Clin Cancer Res
|
2004
|
1.07
|
|
27
|
Effect of long-term storage in TRIzol on microarray-based gene expression profiling.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.04
|
|
28
|
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.
|
Blood
|
2012
|
1.03
|
|
29
|
Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo.
|
Blood
|
2004
|
1.03
|
|
30
|
p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.
|
Cancer Res
|
2012
|
1.02
|
|
31
|
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
|
Cancer
|
2008
|
1.02
|
|
32
|
Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.
|
Cancer Sci
|
2014
|
1.02
|
|
33
|
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets.
|
J Transl Med
|
2004
|
1.01
|
|
34
|
Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma.
|
Blood
|
2011
|
1.01
|
|
35
|
Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry.
|
Proteomics
|
2004
|
1.00
|
|
36
|
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
|
Br J Haematol
|
2010
|
1.00
|
|
37
|
Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma.
|
Exp Hematol
|
2011
|
0.99
|
|
38
|
IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
|
Blood
|
2009
|
0.98
|
|
39
|
Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma.
|
J Infect Dis
|
2006
|
0.97
|
|
40
|
Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells.
|
Mol Ther
|
2008
|
0.97
|
|
41
|
MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response.
|
Haematologica
|
2011
|
0.97
|
|
42
|
Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models.
|
Vaccine
|
2007
|
0.96
|
|
43
|
Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
|
J Control Release
|
2006
|
0.96
|
|
44
|
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
|
Clin Cancer Res
|
2013
|
0.96
|
|
45
|
A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones.
|
J Immunol Methods
|
2007
|
0.95
|
|
46
|
Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth.
|
Cancer Res
|
2008
|
0.94
|
|
47
|
Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.
|
J Immunol
|
2013
|
0.94
|
|
48
|
Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity.
|
Blood
|
2009
|
0.93
|
|
49
|
Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma.
|
Clin Cancer Res
|
2009
|
0.92
|
|
50
|
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
|
Br J Haematol
|
2011
|
0.92
|
|
51
|
Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis.
|
J Leukoc Biol
|
2004
|
0.90
|
|
52
|
Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
|
Haematologica
|
2002
|
0.89
|
|
53
|
A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma.
|
Blood
|
2007
|
0.89
|
|
54
|
The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.88
|
|
55
|
Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma.
|
Cancer
|
2007
|
0.87
|
|
56
|
Identification of human idiotype-specific T cells in lymphoma and myeloma.
|
Curr Top Microbiol Immunol
|
2011
|
0.86
|
|
57
|
In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
|
Mol Cancer Ther
|
2013
|
0.86
|
|
58
|
A novel proteoliposomal vaccine elicits potent antitumor immunity in mice.
|
Blood
|
2007
|
0.85
|
|
59
|
Prospective isolation of clonogenic mantle cell lymphoma-initiating cells.
|
Stem Cell Res
|
2010
|
0.85
|
|
60
|
Molecular analysis of light-chain switch and acute lymphoblastic leukemia transformation in two follicular lymphomas: implications for lymphomagenesis.
|
Leuk Lymphoma
|
2006
|
0.85
|
|
61
|
Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytes.
|
Clin Cancer Res
|
2011
|
0.84
|
|
62
|
Therapeutic idiotype vaccines in B lymphoproliferative diseases.
|
Expert Opin Biol Ther
|
2004
|
0.83
|
|
63
|
Therapeutic lymphoma vaccines: importance of T-cell immunity.
|
Expert Rev Vaccines
|
2006
|
0.83
|
|
64
|
Immune evasion of mantle cell lymphoma: expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells.
|
Haematologica
|
2013
|
0.83
|
|
65
|
Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
|
Clin Cancer Res
|
2004
|
0.82
|
|
66
|
Targeting cell surface β2 -microglobulin by pentameric IgM antibodies.
|
Br J Haematol
|
2011
|
0.82
|
|
67
|
Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.
|
Blood
|
2012
|
0.82
|
|
68
|
Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen.
|
J Immunol
|
2013
|
0.81
|
|
69
|
Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines.
|
Vaccine
|
2010
|
0.80
|
|
70
|
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.
|
Int J Cancer
|
2014
|
0.80
|
|
71
|
Prognostic significance of serum B-lymphocyte stimulator in Hodgkin's lymphoma.
|
Haematologica
|
2007
|
0.79
|
|
72
|
Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression.
|
PLoS One
|
2013
|
0.78
|
|
73
|
Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production.
|
Br J Haematol
|
2012
|
0.78
|
|
74
|
Vaccine therapy for B-cell lymphomas: next-generation strategies.
|
Hematology Am Soc Hematol Educ Program
|
2007
|
0.78
|
|
75
|
Elevated serum BLyS levels in patients with non-Hodgkin lymphoma.
|
Leuk Lymphoma
|
2007
|
0.77
|
|
76
|
Therapeutic vaccine for lymphoma.
|
Yonsei Med J
|
2007
|
0.77
|
|
77
|
Translational development of vaccination strategies in follicular NHL.
|
Best Pract Res Clin Haematol
|
2011
|
0.77
|
|
78
|
Idiotype vaccination as consolidation therapy: time for integration into standard of care for follicular lymphoma?
|
J Clin Oncol
|
2011
|
0.77
|
|
79
|
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
|
Br J Haematol
|
2013
|
0.77
|
|
80
|
T cells and T cell tumors efficiently generate antigen-specific cytotoxic T cell immunity when modified with an NKT ligand.
|
Oncoimmunology
|
2012
|
0.77
|
|
81
|
Prime-boost vaccination using chemokine-fused gp120 DNA and HIV envelope peptides activates both immediate and long-term memory cellular responses in rhesus macaques.
|
J Biomed Biotechnol
|
2010
|
0.76
|
|
82
|
Models for lymphoma.
|
Curr Protoc Immunol
|
2002
|
0.76
|
|
83
|
Cloning of B cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera.
|
J Immunol Methods
|
2006
|
0.75
|
|
84
|
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.75
|
|
85
|
Monocyte-derived dendritic cells: a promising armament for immunotherapy in human malignancies.
|
Clin Cancer Res
|
2005
|
0.75
|
|
86
|
Lymphoma vaccine therapy: next steps after a positive, controlled phase III clinical trial.
|
Semin Oncol
|
2012
|
0.75
|
|
87
|
In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
|
Leuk Lymphoma
|
2003
|
0.75
|
|
88
|
Vaccination strategies for lymphomas.
|
Curr Oncol Rep
|
2003
|
0.75
|
|
89
|
Launching of american journal of blood research.
|
Am J Blood Res
|
2011
|
0.75
|
|
90
|
90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.
|
Br J Haematol
|
2014
|
0.75
|
|
91
|
American Journal of Blood Research: Editorial Board (2011) e-Century Publishing Corporation.
|
Am J Blood Res
|
2011
|
0.75
|